ProCE Banner Activity

New Developments in Pulmonary Arterial Hypertension: A Clinician’s Perspective

Clinical Thought

Expert faculty discuss key points from this year’s Cardiology and Pulmonary Summit for APPs (CAPSAPP) presentation on pulmonary arterial hypertension, including diagnosis, current treatments, and future directions.

Released: October 27, 2023

Expiration: October 27, 2024

Share

Faculty

Melisa A. Wilson

Melisa A. Wilson, DNP, APRN, ACNP, BC

APP Division Director- HLV
Executive Committee Chair
AdventHealth Medical Group Central Florida Division
Pulmonary Hypertension Program Coordinator
Advanced Lung Disease at Orlando
Orlando, Florida

Provided by

Provided by Partners for Advancing Clinical Education (PACE), in partnership with the Academy of Physicians Associates in Cardiology (APAC) and the Association of Pulmonary Advanced Practice Providers (APAPP)

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme, LLC.

Merck Sharp & Dohme, LLC

Partners

Academy of Physician Associates in Cardiology (APAC)

ProCE Banner

Association of Pulmonary Advanced Practice Providers (APAPP)

ProCE Banner

Disclosure

Primary Author

Melisa A. Wilson, DNP, APRN, ACNP, BC

APP Division Director- HLV
Executive Committee Chair
AdventHealth Medical Group Central Florida Division
Pulmonary Hypertension Program Coordinator
Advanced Lung Disease at Orlando
Orlando, Florida

Melisa A. Wilson, DNP, APRN, ACNP, BC: consultant/advisor/speaker: Bayer, Gossamer Bio, Janssen, Merck, United Therapeutics; researcher: Insmed, Merck, United Therapeutics.